Baseline characteristics
| Characteristic . | N = 187 (%) . |
|---|---|
| Sex | |
| Female | 99 (53) |
| Male | 88 (47) |
| Age, y (range) | 62 (50-69) |
| Elevated LDH | 42 (28) |
| Unknown | 35 |
| Hemoglobin <12 g/dL | 34 (21) |
| Unknown | 26 |
| Clinical stage | |
| 1-2∗ | 71 (41) |
| 3-4 | 104 (59) |
| Unknown | 12 |
| >4 nodal sites | 55 (30) |
| Unknown | 3 |
| Disease bulk | |
| <5 cm | 122 (74) |
| 5-10 cm | 35 (21) |
| ≥10 cm | 8 (4.9) |
| Unknown | 23 |
| FLIPI score | |
| 0-1 | 61 (44) |
| 2 | 35 (25) |
| 3+ | 43 (31) |
| Unknown | 48 |
| Bone marrow involvement (morphology) | 53 (46) |
| Unknown | 71 |
| Viral status | |
| Hepatitis B status | |
| Previous infection | 6 (3.2) |
| Susceptible | 123 (66) |
| Unknown | 58 |
| Hepatitis C antibody | |
| Positive | 4 (2.1) |
| Negative | 120 (64) |
| Unknown | 63 |
| Initial management | |
| Observation | 89 (48) |
| Radiation | 18 (9.6) |
| Anti-CD20 mAb | 26 (14) |
| Chemoimmunotherapy | 44 (24) |
| Other | 10 (5.3) |
| Characteristic . | N = 187 (%) . |
|---|---|
| Sex | |
| Female | 99 (53) |
| Male | 88 (47) |
| Age, y (range) | 62 (50-69) |
| Elevated LDH | 42 (28) |
| Unknown | 35 |
| Hemoglobin <12 g/dL | 34 (21) |
| Unknown | 26 |
| Clinical stage | |
| 1-2∗ | 71 (41) |
| 3-4 | 104 (59) |
| Unknown | 12 |
| >4 nodal sites | 55 (30) |
| Unknown | 3 |
| Disease bulk | |
| <5 cm | 122 (74) |
| 5-10 cm | 35 (21) |
| ≥10 cm | 8 (4.9) |
| Unknown | 23 |
| FLIPI score | |
| 0-1 | 61 (44) |
| 2 | 35 (25) |
| 3+ | 43 (31) |
| Unknown | 48 |
| Bone marrow involvement (morphology) | 53 (46) |
| Unknown | 71 |
| Viral status | |
| Hepatitis B status | |
| Previous infection | 6 (3.2) |
| Susceptible | 123 (66) |
| Unknown | 58 |
| Hepatitis C antibody | |
| Positive | 4 (2.1) |
| Negative | 120 (64) |
| Unknown | 63 |
| Initial management | |
| Observation | 89 (48) |
| Radiation | 18 (9.6) |
| Anti-CD20 mAb | 26 (14) |
| Chemoimmunotherapy | 44 (24) |
| Other | 10 (5.3) |
LDH, lactate dehydrogenase.
Not all patients with stage 1 to 2 disease underwent baseline bone marrow examination (refer to the text).